18:17 , Jan 11, 2019 |  BC Week In Review  |  Company News

Regeneron, Sanofi narrow focus of immuno-oncology deal

By narrowing the focus of a 2015 immuno-oncology deal, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) gains more freedom to play in its combinations sandbox as partner Sanofi (Euronext:SAN; NASDAQ:SNY) turns to other immuno-oncology agents in its pipeline....
00:11 , Jan 8, 2019 |  BC Extra  |  Company News

Regeneron, Sanofi narrow focus of immuno-oncology deal

By narrowing the focus of a 2015 immuno-oncology deal, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) gains more freedom to play in its combinations sandbox as partner Sanofi (Euronext:SAN; NASDAQ:SNY) turns to other immuno-oncology agents in its pipeline....
23:11 , Aug 28, 2018 |  BC Extra  |  Company News

Management tracks: BMS, Roche

Bristol-Myers Squibb Co. (NYSE:BMY) said Christopher Boerner will become EVP and Chief Commercial Officer. He succeeds Murdo Gordon, who departed the company last month to become EVP of global commercial operations at Amgen Inc. (NASDAQ:AMGN)...
23:12 , Jul 17, 2018 |  BC Extra  |  Company News

Management tracks: Silence, Apeiron

RNA therapeutics company Silence Therapeutics plc (LSE:SLN) hired David Horn Solomon as CEO. He was CEO at Akari Therapeutics plc (NASDAQ:AKTX). Immuno-oncology company Apeiron Biologics AG (Vienna, Austria) said CEO Hans Loibner has retired. The...
23:29 , Oct 16, 2017 |  BC Extra  |  Company News

Management tracks: Apeiron, Tetraphase

Immuno-oncology company Apeiron Biologics AG (Vienna, Austria) hired Peter Llewellyn-Davies as CFO and CBO. He was CFO and CBO at Medigene AG (Xetra:MDG1). Infectious disease company Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) named Kamalam Unninayar CFO. She...
22:22 , May 11, 2017 |  BC Week In Review  |  Clinical News

EC approves EUSA's dinutuximab beta for high-risk neuroblastoma

EUSA Pharma Ltd. (Hemel Hempstead, U.K.) said the European Commission approved an MAA for dinutuximab beta (APN311) to treat high-risk neuroblastoma in patients ages ≥12 months. Last year, Apeiron Biologics AG (Vienna, Austria) granted EUSA...
05:16 , Mar 31, 2017 |  BC Week In Review  |  Clinical News

Isqette regulatory update

EMA's CHMP recommended approval of an MAA from Apeiron for Isqette dinutuximab beta to treat high-risk neuroblastoma under EMA's exceptional circumstances clause. It is recommended in patients ages ≥12 months who achieved a partial response...
21:32 , Mar 24, 2017 |  BC Extra  |  Company News

CHMP backs Orphan candidates, PD-1 mAbs

On Friday, EMA's CHMP recommended approval of several candidates, including Orphan disease therapies Isqette dinutuximab beta ( APN311 ) from Apeiron Biologics AG (Vienna, Austria) and Refixia nonacog beta pegol from Novo Nordisk A/S (CSE:NVO;...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Company News

Apeiron Biologics, EUSA Pharma deal

Apeiron granted EUSA exclusive, worldwide rights to commercialize pediatric neuroblastoma candidate Isqette dinutuximab beta ( APN311 ). The chimeric mAb against ganglioside GD2 (GD2) is under review in the EU. EUSA plans to submit a...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Company News

Apeiron Biologics, Columbia University deal

The university’s Columbia Technology Ventures tech transfer office granted Apeiron exclusive, worldwide rights to develop and commercialize IP related to active cellular immunotherapies that inhibit casitas B cell lymphoma-b (Cbl-b) in T cells to treat...